Market leadership, fast
Phenotypeca is developing a portfolio of premium biosimilars ready for out-license to deliver market-dominating advantages. Our QTL technology creates optimised manufacturing strains with characteristics that are customised to the needs of the highly competitive biosimilars market, while retaining bioequivalence. The valuable differentiators enabled by this approach are what make our biosimilars ‘premium’.
The benefits of creating premium biosimilars using QTL technology include reducing or removing downstream processing; lowering the costs of manufacture; significantly reducing the scale of plant required; making technically complex proteins where the reference molecule owner retains secret know-how; and creating proteins of consistently high quality with characterisation specifications that exceed those of the regulator.
You might be an established biosimilar business, a potential new entrant, or looking for a low-risk path to high growth. In all these cases, licensing a premium biosimilar provides differentiators that enable your product to stand out in a competitive marketplace and drive growth. At the point of licensing, our products are packaged and ready for development and commercialisation.
What happens next
Your first step is to contact Phenotypeca at the bottom of this page. Together we can then look through our growing library of patented premium biosimilars to identify licensing opportunities for specific territories and indications. New market opportunities for the creation of premium biosimilars continue to be revealed by our ongoing review of the entire FDA and EMA regulated formulary of recombinant protein therapeutics.
Upon licensing you will undertake the regulatory approval development for bioequivalence and take responsibility for commercialisation in the territories of interest. Manufacturing can be arranged through skilled manufacturing contractors if you choose not to do so yourselves.
